Summary

Aarti Drugs Limited, a Mumbai based diversified and fully integrated pharmaceutical company, has announced its unaudited financial results for the quarter and half year ended 30th September 2025. The company reported a 9% YoY growth in revenue, with EBITDA and PAT also showing significant increases.

Key Highlights

1. 1

   Revenue for Q2 FY26 stood at Rs. 652.9 crore, a 9% YoY growth

2. 2

   EBITDA for Q2 FY26 stood at Rs. 84.4 crore, a 23% YoY increase

3. 3

   PAT for Q2 FY26 stood at Rs. 45.2 crore, a 29% YoY increase

4. 4

   H1 FY26 revenue stood at Rs. 1,243.7 crore, an 8% YoY growth

5. 5

   H1 FY26 EBITDA stood at Rs. 158.8 crore, an 18% YoY increase

6. 6

   H1 FY26 PAT stood at Rs. 99.1 crore, a 45% YoY increase

7. 7

   API segment contributed 515.9 crores to Q2 FY26 revenue

8. 8

   Formulations segment contributed 82.4 crores to Q2 FY26 revenue

9. 9

   Specialty Chemicals segment contributed 37.3 crores to Q2 FY26 revenue

10. 10

    Intermediates & Others segment contributed 21.3 crores to Q2 FY26 revenue

11. 11

    Standalone business contributed 89% to the consolidated revenue

12. 12

    Domestic revenue was down 7% YoY and export revenue increased by 33% YoY